×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
戻る Agenda
Session 6: Track C: Best Practices in Policy Development and Direction
Session Chair(s)
Lissa Murseli
Manager
Health Canada, Canada
This session will give an overview of relevant policy areas in Canada, such as cannabis and/or opioids. Speakers will highlight key policy areas that are underway or emerging. The session will describe some lessons learned or best practices in these policy areas, including engagement of relevant players in the policy development process.
Learning Objective : At the conclusion of this session, participants should be able to:- Explain the Canadian context of key policy issues in Canadian healthcare product policy
- Describe existing and emerging healthcare product areas in Canada
- Discuss the policy development process and best practices for stakeholder engagement
Speaker(s)
Citizen-Focused Drug Policy Development: Working with (and for) People with Lived and Living Experience with Drug Use
Ian Hodges
Health Canada, Canada
Manager, Policy Development, Office of Drug Policy and Science
Proactive Monitoring: A New Approach to Health Canada’s Oversight of Health Products Advertising
Alain G. Musende, PhD
Marketed Health Products Directorate, Health Canada, Canada
Manager, Section for Transparency and Advertising Regulatory Surveillance
A Discussion of Innovation and Collaboration Frameworks for Medical Cannabis
Setu Purohit, JD
Avicanna Inc., Canada
Co-Founder, President, Chief Legal Officer